Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
6.45
-0.15 (-2.27%)
Mar 25, 2025, 4:00 PM EST - Market closed
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Fennec Pharmaceuticals stock have an average target of 14, with a low estimate of 13 and a high estimate of 15. The average target predicts an increase of 117.05% from the current stock price of 6.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +101.55% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +101.55% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +101.55% | Aug 22, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $17 → $15 | Strong Buy | Maintains | $17 → $15 | +132.56% | Aug 14, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +163.57% | May 15, 2024 |
Financial Forecast
Revenue This Year
61.32M
from 47.54M
Increased by 28.99%
Revenue Next Year
100.08M
from 61.32M
Increased by 63.21%
EPS This Year
0.17
from -0.00
EPS Next Year
1.46
from 0.17
Increased by 743.14%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 96.9M | 126.3M | 149.2M | ||
| Avg | 61.3M | 100.1M | 123.2M | ||
| Low | 45.4M | 65.2M | 90.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 103.8% | 106.0% | 49.1% | ||
| Avg | 29.0% | 63.2% | 23.1% | ||
| Low | -4.5% | 6.3% | -10.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.51 | 2.22 | 2.09 | ||
| Avg | 0.17 | 1.46 | 1.83 | ||
| Low | -0.38 | 0.74 | 1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,177.7% | 42.9% | ||
| Avg | - | 743.1% | 25.2% | ||
| Low | - | 323.9% | 7.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.